Antidepressant Medications and Weight Change: A Narrative Review
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Antidepressant medications are the first‐line treatment option for moderate to severe major depressive disorder. However, most antidepressants have numerous documented adverse events, including cardiometabolic effects and weight gain, which are major public health concerns. Antidepressant agents provide varying risk of associated weight gain, including significant within‐class differences. Some agents, such as mirtazapine, show significant levels of weight gain, while others, such as bupropion, demonstrate weight‐loss effects. Current findings suggest the role of histamine and serotonin off‐target appetite‐promoting pathways in adverse weight‐gain effects. Therefore, controlling for undesired weight effects is an important consideration for the selection of antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Hay, S. I., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32130-x · Cited by 2,083
Self-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Serretti, A., & Mandelli, L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05346blu · Cited by 621 · cited 10×
“69 kg) ≥ 4 months following treatment (35).”
BackgroundResultInfluentialDuloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565 · cited 1×
“SNRI: duloxetine Duloxetine is used for the treatment of MDD and is also approved for use in the treatment of chronic pain (79).”
MethodMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Self-citationThe importance of norepinephrine in depression
Briley, M., & Chantal, M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19619 · Cited by 373 · cited 1×
“SNRI use has been shown to normalize abnormal metabolism in the amygdala and prefrontal cortex (36).”
BackgroundTranylcypromine versus imipramine in anergic bipolar depression
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.7.910 · Cited by 360
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · Focus · doi:10.1176/appi.focus.16407 · Cited by 328
Masand, P., & Gupta, S. (2002) · Annals of Clinical Psychiatry · doi:10.3109/10401230209147454 · Cited by 311 · cited 1×
“increase in weight over long-term treatment (69,89).”
Lambert, G., Johansson, M., Ågren, H., & Friberg, P. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.787 · Cited by 303
Evidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302 · cited 2×
“of the serotonin channel than the norepinephrine transporter (38).”
BackgroundAddressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299 · cited 2×
“A review of contemporary antidepressant drugs found TCAs to be frequently associated with weight gain during both acute and long-term exposure (35,61).”
BackgroundLong-term antidepressant use: patient perspectives of benefits and adverse effects
Cartwright, C., Gibson, K., Read, J., Cowan, O., & Dehar, T. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s110632 · Cited by 242
Lopez, J. P., Fiori, L. M., Cruceanu, C., Lin, R., Labonte, B., Cates, H. M., Heller, E. A., Vialou, V., Ku, S. M., Gerald, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms15497 · Cited by 201 · cited 1×
“Thus, they are one of the most commonly prescribed drug classes worldwide (5,6).”
BackgroundVan Reedt Dortland, A. K. B., Giltay, E. J., Van Veen, T., Zitman, F. G., & Penninx, B. W. J. H. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01565.x · Cited by 191
Compton, M. T., Daumit, G. L., & Druss, B. G. (2006) · Harvard Review of Psychiatry · doi:10.1080/10673220600889256 · Cited by 177 · cited 1×
“3% of patients experienced adverse effects of weight gain (14), which is relevant given that obesity is two to three times more common in individuals with mental illness compared with the general population (15).”
BackgroundClinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165 · cited 1×
“Clinical trials have suggested that ketamine and vortioxetine may be efficacious options for the treatment of MDD with minimal effects on weight (94,104) .”
BackgroundPehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use
Blumenthal, S. R., Castro, V. M., Clements, C. C., Rosenfield, H. R., Murphy, S. N., Fava, M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.414 · Cited by 151 · cited 5×
“In contrast, Blumenthal et al. (2014) reported a mean weight change of + 0.5 kg (n = 326) at 9 months (69).”
BackgroundInfluentialMedications that cause weight gain and alternatives in Canada: a narrative review
Wharton, S., Raiber, L., Serodio, K., Lee, J., & Christensen, R. A. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s171365 · Cited by 100 · cited 18×
“Moreover, a review of medical health records found the least long-term weight change in patients using fluoxetine compared with other SSRIs.”
BackgroundInfluentialMaina, G., Albert, U., Salvi, V., & Bogetto, F. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1011 · Cited by 79
Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000057 · Cited by 77
Rao, K. S., Menon, P. K., Hilman, B. C., Sebastian, C. S., & Bairnsfather, L. (1988) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(88)90075-9 · Cited by 51 · cited 2×
“TCAs demonstrate these effects as they are antagonists of the histamine and muscarinic acetylcholine receptors (20-22).”
BackgroundEvaluation of vilazodone for the treatment of depressive and anxiety disorders
Stuivenga, M., Giltay, E. J., Cools, O., Roosens, L., Neels, H., & Sabbe, B. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1549542 · Cited by 24
Sansone, R. A., Wiederman, M. W., & Shrader, J. A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00028 · Cited by 6
Cited by
Connecting insufficient sleep and insomnia with metabolic dysfunction
Duan, D., Kim, L. J., Jun, J. C., & Polotsky, V. Y. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14926 · Cited by 110
Treating the Chronic Disease of Obesity
Gossmann, M., Butsch, W. S., & Jastreboff, A. M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.005 · Cited by 33
Garvey, L., Benson, A. C., Benger, D., Short, T., Banyard, H., & Edward, K. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13089 · Cited by 24
Lyu, B., Chang, A. R., Inker, L. A., Selvin, E., Grams, M. E., & Shin, J.-I. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100249 · Cited by 22
Shea, S., Lionis, C., Kite, C., Atkinson, L., Chaggar, S. S., Randeva, H. S., & Kyrou, I. (2021) · Biomedicines · doi:10.3390/biomedicines9111697 · Cited by 4
Metadata
- Authors
- Gill, H., Gill, B., El‐Halabi, S., Chen‐Li, D., Lipsitz, O., Rosenblat, J. D., Van Rheenen, T. E., Rodrigues, N. B., Mansur, R. B., Majeed, A., Lui, L. M. W., Nasri, F., Lee, Y., & Mcintyre, R. S.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2020-10-06
- Volume
- 28
- Issue
- 11
- Pages
- 2064-2072
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W3092577559
- Cited by
- 193
- References
- 30
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.